TREUR
Trillium Therapeutics Inc
Canada-based clinical stage immuno-oncology company developing CD47-targeting cancer therapies
CUSIP: 89620X506HealthcareCA1 holder
Total Value
$5.99M
Total Shares
341.0K
Net Share Change
+341.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
Fairfax Financial Holdings
$5.99M341.0K sharesNEW